Key terms
About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest REGN news
Today
1:36am ET
Buy Rating Affirmed for Regeneron on Eylea HD Success and Innovative Obesity Program
Mar 13
7:09am ET
Regeneron price target raised to $1,115 from $1,104 at Morgan Stanley
Mar 13
5:01am ET
Analysts’ Top Healthcare Picks: Cooper Co (COO), Regeneron (REGN)
Mar 12
9:51am ET
Oracle, Dollar General upgraded: Wall Street’s top analyst calls
Mar 11
4:11pm ET
Regeneron initiated with an Outperform at Bernstein
Mar 11
7:37am ET
Regeneron says FDA has extended approval of Praluent
Mar 08
7:30am ET
Analysts Are Bullish on Top Healthcare Stocks: Amgen (AMGN), Regeneron (REGN)
Mar 08
7:06am ET
Regeneron published one-year results from PULSAR, PHOTON, met primary endpoint
Mar 05
7:28am ET
2seventy bio: Close of asset sale to Regeneron seen in 1H24
Feb 27
8:34am ET
Regeneron price target raised to $1,184 from $1,096 at RBC Capital
Feb 27
7:51am ET
Analysts Are Bullish on Top Healthcare Stocks: ANI Pharmaceuticals (ANIP), Boston Scientific (BSX)
Feb 27
7:47am ET
Truist Financial Gives a Buy Rating to Regeneron (REGN)
Feb 27
12:30am ET
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Relay Therapeutics (RLAY) and Regeneron (REGN)
Feb 23
7:25am ET
Buy Rating Affirmed: Regeneron’s Strategic Growth in Obesity Metabolic Space
Feb 23
5:16am ET
Regeneron, Sanofi announce FDA acceptance for priority review of Dupixent sBLA
Feb 21
7:35am ET
Regeneron sees FY24 adjusted EPS $1.42-$1.49, consensus $1.77
Feb 21
7:18am ET
Regeneron announces U.S. FDA accepted priority review for BLA for linvoseltamab
Feb 16
5:26am ET
Regeneron, Sanofi announce MHLW in Japan approves Dupixent
Feb 15
9:44am ET
Regeneron price target raised to $1,060 from $920 at Argus
Feb 15
3:20am ET
Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT), Regeneron (REGN) and Merck & Company (MRK)
Feb 09
4:14pm ET
Regeneron exec LaRosa sells 1,000 common shares
Feb 07
8:25am ET
Buy Rating Affirmed for Regeneron on Strong Drug Pipeline and Market Growth Potential
Feb 06
7:50am ET
Analysts’ Top Healthcare Picks: Intuitive Surgical (ISRG), Vertex Pharmaceuticals (VRTX)
Feb 06
7:25am ET
Strong Buy: Regeneron’s Growth Potential and Strategic R&D Investments
Feb 06
1:00am ET
Regeneron Pharmaceuticals Is Worried About This – Should You Be Worried Too?
Feb 05
10:11am ET
Regeneron price target raised to $1,135 from $1,045 at Truist
Feb 05
9:54am ET
Regeneron price target raised to $1,082 from $1,055 at BMO Capital
Feb 05
8:52am ET
Regeneron price target raised to $1,110 from $1,076 at RBC Capital
Feb 05
8:43am ET
Regeneron price target raised to $1,152 from $1,066 at Canaccord
Feb 05
8:20am ET
Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Arcellx Inc (ACLX)
Feb 05
8:10am ET
Analysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Boston Scientific (BSX)
REGN Financials
Key terms
Ad Feedback
REGN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
REGN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range